Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

(2016) Erwin De Cock et al.   Cancer Medicine

Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study

(2014) Antonio Salar et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous rituximab: a practical approach?

(2014) Kensei Tobinai   LANCET ONCOLOGY

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

(2014) Andrew Davies et al.   LANCET ONCOLOGY

Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom

(2014) Simon Rule et al.   JOURNAL OF MEDICAL ECONOMICS

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects

(2013) Jim McCambridge et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Rituximab and chemotherapy in diffuse large B-cell lymphoma

(2009) Anne Sonet et al.   Expert Review of Anticancer Therapy